Table 2 Sample characteristics and association with SLLP1 expression
From: Cancer-testis antigen SLLP1 represents a promising target for the immunotherapy of multiple myeloma
Characteristics | SLLP1-positive | SLLP1-negative | Sig. |
|---|---|---|---|
Total (NÂ =Â 394) | 99 (25.1) | 296 (74.9) | Â |
Age at time of sample collection (years) | |||
 ≤60 | 64 (21.1) | 240 (78.9) | 0.001 |
 >60 | 35 (38.9) | 55 (61.1) |  |
BM-infiltrating plasma cells (%) | |||
 <10 | 24 (11.6) | 183 (88.4) | 0.000 |
 10–30 | 19 (33.3) | 38 (66.7) |  |
 ≥30 | 37 (53.6) | 32 (46.4) |  |
Serum paraprotein (g/dL) | |||
 <5 (IgG), <3 (IgA) | 8 (14.3) | 48 (85.7) | 0.061 |
 5–7 (IgG), 3–5 (IgA) | 7 (24.1) | 22 (75.9) |  |
 >7 (IgG), >5 (IgA) | 57 (30.0) | 133 (70.0) |  |
Involved serum free light chains (mg/L) | |||
 ≤100 | 6 (30.0) | 14 (70.0) | 0.129 |
 >100 | 3 (10.0) | 27 (90.0) |  |
Serum albumin (g/dL) | |||
 ≥3.5 | 67 (21.8) | 241 (78.2) | 0.006 |
 <3.5 | 19 (43.2) | 25 (56.8) |  |
β2-microglobulin (mg/L) | |||
 <3.5 | 22 (18.6) | 96 (81.4) | 0.019 |
 ≥3.5 | 18 (35.3) | 33 (64.7) |  |
Serum LDH (U/L) | |||
 ≤300 | 75 (23.0) | 251 (77.0) | 0.082 |
 >300 | 13 (35.1) | 23 (63.9) |  |
Hemoglobin (g/dL) | |||
 >10.0 | 6 (27.3) | 16 (72.7) | 0.043 |
 9.9–8.5 | 16 (41.0) | 23 (59.0) |  |
 <8.5 | 55 (22.4) | 190 (77.6) |  |
Serum calcium (mmol/L) | |||
 ≤2.6 | 79 (22.8) | 267 (77.2) | 0.015 |
 >2.6 | 9 (47.4) | 10 (52.6) |  |
Serum creatinine (mg/dL) | |||
 ≤2.0 | 78 (22.5) | 269 (77.5) | 0.008 |
 >2.0 | 9 (50.0) | 9 (50.0) |  |
Treatment status | |||
 Untreated | 25 (44.6) | 31 (55.4) | 0.003 |
 Chemotherapy | 8 (22.2) | 28 (77.8) |  |
 AutoSCT | 19 (29.2) | 46 (70.8) |  |
 AlloSCT | 47 (19.9) | 189 (80.1) |  |